Anbio Biotechnology designs, manufactures through outsourced partners, and distributes in vitro diagnostic assays and devices for laboratory, point-of-care, and home use across global markets. The company generates revenue from product sales of diagnostic tools serving medical institutions, clinical customers, and distribution partners, recognizing revenue upon shipment with payment terms typically spanning 30 to 90 days. Operating with a capital-light model that leverages external OEM manufacturers rather than in-house production, the company maintains an experienced management team focused on advancing non-COVID diagnostic product commercialization and expanding market reach through strategic partnerships and distribution channels.